BioXcel granted extension to regain compliance with Nasdaq listing requirement

BioXcel Therapeutics (BTAI) announced that the Nasdaq Hearings Panel granted the Company’s request to continue its listing on The Nasdaq Stock Market. During a Nasdaq Panel hearing held on May 1, 2025, the Panel reviewed the Company’s plan and strategies to regain compliance with Listing Rule 5550(b)(2). As a result of the hearing, the Panel granted the Company’s request for continued listing on The Nasdaq Stock Market and provided the Company until September 16, 2025 to regain compliance, subject to the Company meeting certain interim conditions. BioXcel Therapeutics is committed to executing on its compliance plan to meet the applicable requirements within the specified time frame.